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ABSTRACT
Objective: The objective of this work was to synthesize and evaluate antimicrobial properties of 1-(4-methyl-6-nitro-2H-benzo[b][1,4]thiazine-
3(4H)-ylidene)hydrazine-1,1-dioxide derivatives.
Methods: These new compounds were synthesized by methylation in 4-N and reacted with hydrazine derivatives and oxidized at the sulfur atom by 
30% hydrogen peroxide to obtain sulfones. All the synthesized compounds were evaluated for antimicrobial activity using the disc diffusion method.
Results: The Fourier transform infrared, 1H nuclear magnetic resonance (NMR), 13CNMR, and mass studies confirm the synthesis of some new 1-(4-methyl-
6-nitro-2H-benzo[b][1,4]thiazine-3(4H)-ylidene)hydrazine-1,1-dioxide derivatives. Compound 6f showed the potent antimicrobial activity.
Conclusion: Result obtained in this research work clearly indicated that the compound 6f having methyl at 2 position and nitro groups at 2′ and 4′ 
position showed the most potent antimicrobial activity.
Keywords: 1,4-Benzothiazines, Sulfones, Hydrazines, Antimicrobial activity.
INTRODUCTION
Research in the synthetic chemistry of 1,4-benzothiazine derivatives 
during the past few decades was mainly attributed to their unique 
chemical, physical, and biological properties [1-7]. The synthesis of the 
sulfoxide system, many sulfones have been shown to exhibit biological 
activity for the industrial and pharmacological applications [8,9]. The 
oxidation of sulfide linkage in 1,4-benzothiazines to dioxide leads to a 
significant class of heterocyclic sulfones from medicinal and structural 
aspects. Alteration of benzothiazine into sulfone has provided an 
opportunity to study the changes in infrared and nuclear magnetic 
resonance (NMR) spectra caused by the conversion of the sulfide 
linkage to sulfones.
In the worldwide as well as in the developing countries, the most 
human death occurs due to infectious bacterial disease. Drug resistance 
in human pathogenic microbes has developed due to the indiscriminate 
use of the commercial antimicrobial drugs for the treatment of the 
infectious disease. Drug resistance is the major obstacle of this era 
which is leading toward mortality and morbidity. This condition 
has been enforced to the researcher to investigate for the new 
antimicrobial substance which is more efficient and having lesser 
side effect with improved physical properties. The alkylation of 4-N 
position of 2H-benzo[1,4]thiazine’s affords bactericidal and antifungal 
derivatives. With the aim to investigate more potent antimicrobial 
activity of structurally related compounds, several 1-(4-methyl-6-
nitro-2H-benzo[b][1,4]thiazin-3(4H)-ylidene)hydrazine-1,1-dioxide 
derivatives 6a-f were synthesized (Fig. 1). The synthesis of compounds 
6a-f started from the treatment of 2-chloro-5-nitroaniline 1 with 
sodium sulfide and sulfur gave sodium-2-amino-4-nitrobenzenethiol 2, 
which was cyclised with β-heloesters in ethanolic solution [10] to yield 
2H-benzo[b][1,4]thiazin-3(4H)-one derivatives 3a-b. Compounds 4a-b 
were synthesized by methylation of compounds 3a-b by methyl iodide 
in dimethyl sulfoxide (DMSO)/ethanol [11], which was refluxed with 
some nitrogen containing nucleophilic hydrazines in methanol [12] to 
yield 1-(4-methyl-6-nitro-2H-benzo[b][1,4]thiazine-3-yl)hydrazines 
5a-f. The further step, that is, the oxidation of the sulfur, was usually 
performed with 30% hydrogen peroxide in glacial acetic acid [13] to 
produce their sulfones 6a-f. The newly synthesized compounds have 




All the chemicals used were of analytical grade. Melting points were 
determined in open capillary tubes and are uncorrected. Purity of 
the compounds was checked by thin layer chromatography on silica 
gel plates with a 0.2 mm thickness. Compounds were powdered, 
mixed with KBr at 1% concentration, and pressed into pellets 
before IR spectra be recorded on Bruker FT/IR Vertex spectrometer. 
1H- and 13C-NMR spectra were recorded on a Bruker Avance II 400 NMR 
spectrometer using DMSO-d6 as solvent, TMS as an internal standard 
and the chemical shifts (δ) are expressed in parts per million (ppm), 
and coupling constants (J) are given in hertz (Hz). Mass spectra were 
recorded on a Waters, Q-TOF MS-ES spectrometer. Elemental analysis 
was done on Carlo Erba 1108 elemental analyzer.
The synthesis, physical, and analytical properties of compounds 2, 3a, 
and 4a has been previously described [10,11].
Synthesis of 2-methyl-6-nitro-2-H-benzo[b][1,4]thiazin-3-one (3b)
Sodium-2-amino-4-nitrobenzenethiol (1.2 g, 0.01 mol) (2) and methyl-
2-chloropropionate (1.1 g, 0.01 mol) were dissolved in 30 ml ethanol. 
About 5 ml of 10% NaOH was added and refluxed for 3 hrs. Product was 
poured in ice, washed with water, and recrystallized from ethanol to 
obtain compound 3b. Light yellow crystal, yield, 93%; m.p. 174-175°C; 
Rf, 0.89 (toluene-ethyl acetate, 7:5); ultraviolet (UV) (DMSO) λmax (log Ɛ) 
346 (4.66) nm; IR (υ cm−1): 3360, 2924, 1671, 1578, 1392, 650; 1H-NMR 
(d ppm, DMSO-d6): 1.5 (d, 3H, J=7 Hz, CH-CH3), 3.7 (q, 1H, H-2), 7.6 
(d, 1H, J=8.4 Hz, H-8), 7.9 (dd, 1H, J=8.6 and 2.2 Hz, H-7), 8.1(d, 1H, 
J=2.4 Hz, H-5), 10.95 (s, 1H, NH); 13C-NMR(d ppm, DMSO-d6): 19.9 (CH3, 
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CH-CH3), 50.5 (CH, C-2), 115.7 (CH, C-5), 116.9 (CH, C-7), 127.9 (CH, 
C-8), 131.4 (C, C-9), 143.3 (C, C-10), 145.0 (C, C-6), 169.4 (C, C-3); ESMS 
m/z (%): 224 (55), 195 (38), 181 (100), 143 (24), 95 (12). Analysis 
calculated for C9H8N2O3S: C, 48.21; H, 3.60; N, 12.49; S, 14.30. Found: C, 
48.23; H, 3.58; N, 12.53; S, 14.31.
Synthesis of 2,4-dimethyl-6-nitro-2-H-benzo[b][1,4]thiazin-3-one 
(4b)
2-Methyl-6-nitro-2-H-benzo[b][1,4]thiazin-3(4H)-one 3b (2.4 g, 0.01 
mol) and potassium hydroxide (1.1g, 0.02 mol) were dissolved in DMSO 
(20 ml) and ethanol (25 ml). The mixture was stirred for 10 minutes 
before methyl iodide (1.2 ml, 0.02 mol) was added. Solution was heated 
at 50°C with stirring for 15 hrs. After cooling, water was added and the 
organic phase was extracted with cyclohexane (3×50 ml) and purified 
by column chromatography on silica gel with a mixture of toluene-
ethyl acetate (8:2) as eluent. Yellow oil, yield, 80%; Rf, 0.52 (toluene-
ethyl acetate, 7:5); UV (DMSO) λmax (log Ɛ) 211 (4.84) nm; IR (υ cm−1): 
2924, 1670, 1591, 1443, 1245, 640; 1H-NMR (d ppm, DMSO-d6): 1.5 
(d, 3H, J=7 Hz, CH-CH3), 3.4 (s, 3H, N-CH3), 3.7 (q, 1H, H-2), 7.7 (d, 1H, 
J=8.5 Hz, H-8), 7.9 (dd, 1H, J=8.5 and 2.2 Hz, H-7), 8.0 (d, 1H, J=2.2 Hz, 
H-5); 13C-NMR(d ppm, DMSO-d6): 19.9 (CH3, CH-CH3), 32.1 (CH3, N-CH3), 
40.5 (CH, C-2), 116.4 (CH, C-5), 117.5 (CH, C-7), 128.5 (CH, C-8), 131.9 
(C, C-9), 140.4 (C, C-10), 146.6 (C, C-6), 165.1 (C, C-3); ESMS m/z (%): 
238 (24), 195 (100), 166 (13), 154 (54), 95 (12). Analysis calculated for 
C9H8N2O3S: C, 50.41; H, 4.23; N, 11.76; S, 13.46. Found: C, 50.37; H, 4.27; 
N, 11.73; S, 14.00.
General method for the synthesis of compounds 5a-f
2-substituted-4-methyl-6-nitro-benzo[b][1,4]thiazin-3(4H)-one (4a-b) 
(0.01 mol) and hydrazine derivative (0.01 mol) were dissolved in 15 ml 
methanol. About 10 ml concentration, HCl was added into reaction 
mixture and heated on a steam bath at 70-80°C for 2 hrs. The reaction 
mixture was concentrated and cooled in an ice bath.
1-(4-Methyl-6-nitro-2H-benzo [b][1,4]thiazin-3(4H)-ylidene)
hydrazine (5a)
The title compound was prepared from 4-methyl-6-nitro-2H-
benzo[b][1,4]thiazin-3(4H)-one (4a) and hydrazine hydrate. Product 
was extracted with cyclohexane (3x50 ml) and purified by column 
chromatography on silica gel with a mixture of toluene-ethyl acetate 
(8:2) as eluent. Light yellow oil; yield, 52; Rf, 0.52 (benzene-acetone, 
1:3); UV (DMSO) λmax (log Ɛ) 217 (4.77) nm; IR (υ cm−1): 3315, 2899, 
1688, 1590, 646; 1H-NMR (d ppm, DMSO-d6, 400 MHz): 2.77 (s, 3H, 
N-CH3), 2.83 (s, 2H, H-2), 7.36 (1H, d, J=8.6 Hz, H-8), 7.59 (1H, d, J=2.5 Hz, 
H-5), 7.91 (1H, dd, J=2.5, 8.6 Hz, H-7), 8.23 (s, 2H, NH2); 13C-NMR (d 
ppm, DMSO-d6, 100 MHz): 30.0 (CH3, N-CH3), 31.1 (CH2, C-2), 107.6 
(CH, C-5), 109.8 (CH, C-7), 123.3 (C, C-9), 128.6 (CH, C-8), 140.7 (C, 
C-10), 145.6 (C, C-6), 153.7 (C, C-3); ESMS m/z (%): 238 (11), 199 (39), 
164 (24), 138 (100), 102 (16), 88 (11), 74(5). Analysis calculated for 
C9H11N3O2S: C, 45.37; H, 4.23; N, 23.51; S, 13.46. Found: C, 45.33; H, 4.26; 
N, 23.55; S, 13.44.
1-(4-methyl-6-nitro-2H-benzo[b][1,4]thiazin-3(4H)-ylidene)-2-
phenylhydrazine (5b)
The title compound was prepared from 4-methyl-6-nitro-2H-benzo[b]
[1,4]thiazin-3(4H)-one (4a) and phenyl hydrazine hydrochloride and 
recrystallized from ethanol. Brown crystals; yield, 66%; m.p. 190-192°C; 
Rf, 0.50 (benzene-acetone, 1:3); UV (DMSO) λmax (log Ɛ) 211 (4.84) nm; 
IR (υ cm−1): 3362, 2898, 1685, 1592, 1442, 1245, 639; 1H-NMR (d ppm, 
DMSO-d6, 400 MHz): 2.73 (s, 3H, N-CH3), 2.91 (s, 2H, H-2), 6.45 (2H, dd, 
J=1.6, J=8.5 Hz, H-2’,6’), 6.65-7.19 (3H, m, H-3’, H-4’, H-5’), 7.22 (1H, d, 
J=8.6 Hz, H-8), 7.31 (1H, d, J=2.5 Hz, H-5), 7.41 (1H, dd, J=2.5, 8.6 Hz, 
H-7), 10.45 (s, 1H, NH); 13C-NMR (d ppm, DMSO-d6, 100 MHz): 30.1 
(CH3, N-CH3), 31.5 (CH2, C-2), 109.5 (CH, C-5), 116.3 (CH, C-2’, C-6’), 
118.8 (C, C-4’), 119.7 (CH, C-7), 123.2 (C, C-9), 127.8 (CH, C-8), 129.7 
(CH, C-3’, C-5’), 140.2 (C, C-10), 147.1 (C, C-1’), 153.3 (C, C-3, C-6); ESMS 
m/z (%): 314 (14), 275 (7), 226 (11), 200 (39), 164 (24), 150 (100), 
136 (12). Analysis calculated for C15H13N5O6S: C, 57.31; H, 4.49; N, 17.82; 
S, 10.20. Found: C, 57.35; H, 4.45; N, 17.86; S, 10.18.
1-(4-methyl-6-nitro-2H-benzo[b][1,4]thiazin-3(4H)-ylidene)-2-
(2,4-dinitrophenyl) hydrazine (5c)
The title compound was prepared from 4-methyl-6-nitro-2H-benzo[b]
[1,4]thiazin-3(4H)-one (4a) and 2,4-m-dinitrophenyl hydrazine and 
recrystallized from ethanol. Orange crystals; yield, 78%; m.p. 140-
142°C; Rf, value: 0.54 (benzene-acetone, 1:3); UV (DMSO) λmax (log Ɛ) 
211 (4.84) nm; IR (υ cm−1): 3310, 2923, 1645, 1577, 1404, 1249, 1093, 
656; 1H-NMR (d ppm, DMSO-d6, 400 MHz): 2.72 (s, 3H, N-CH3), 2.81 (s, 
2H, H-2), 7.22 (1H, d, J=8.6 Hz, H-8), 7.44 (1H, dd, J=2.5, 8.6 Hz, H-7), 
7.48 (1H, d, J=2.5 Hz, H-5), 8.03 (1H, d, J=8.7 Hz, H-6’), 8.68 (1H, dd, 
J=2.6, 8.8 Hz, H-5’), 8.89 (1H, d, J=2.6 Hz, H-3’), 11.34 (br, 1H, NH); 
13C-NMR(d ppm, DMSO-d6, 100 MHz): 30.2 (CH3, N-CH3), 31.3 (CH2, 
C-2), 109.4 (CH, C-5), 119.4 (CH, C-6’, C-7), 121.1 (CH, C-3’), 123.3 (C, 
C-9, C-2’), 127.0 (CH, C-5’), 127.7 (CH, C-8), 140.3 (C, C-10), 142.7 (C, 
C-4’), 147.4 (C, C-1’), 153.6 (C, C-3, C-6); ESMS m/z (%): 404 (10), 
365 (38), 316 (44), 290 (25), 254 (100), 136 (8). Analysis calculated 
for C15H13N5O6S: C, 44.55; H, 2.99; N, 20.78; S, 7.93. Found: C, 44.57; H, 
2.96; N, 20.75; S, 7.96.
1-(2,4-Dimethyl-6-nitro-2H-benzo[b][1,4]thiazin-3(4H)-ylidene)
hydrazine (5d)
The title compound was prepared from 2,4-dimethyl-6-nitro-2H-
benzo[b][1,4]thiazin-3(4H)-one (4b) and hydrazine hydrate. Product 
was extracted with cyclohexane (3x50 ml) and purified by column 
chromatography on silica gel with a mixture of toluene-ethyl acetate 
(8:2) as eluent. Light yellow oil; yield, 70%; Rf, 0.42 (toluene-ethylacetate 
3:2); UV (DMSO) λmax (log Ɛ) 225 (4.49) nm; IR (υ cm−1): 3362, 2828, 
1692, 1523, 1245, 659; 1H-NMR (d ppm, DMSO-d6, 400 MHz): 1.19 (d, 
3H, J=7 Hz, CHCH3), 2.42 (s, 3H, N-CH3), 2.53 (q, 1H, H-2), 7.21 (1H, d, 
J=8.6 Hz, H-8), 7.28 (1H, d, J=2.5 Hz, H-5), 7.41 (1H, dd, J=2.5, 8.6 Hz, 
H-7), 8.51 (s, 2H, NH2); 13C-NMR (d ppm, DMSO-d6, 100 MHz): 15.0 
(CH3, CHCH3), 30.1 (CH3, N-CH3), 34.6 (CH, C-2), 107.7 (CH, C-5), 109.6 
(CH, C-7), 123.3 (C, C-9), 128.0 (CH, C-8), 139.3 (C, C-10), 149.5 (C, C-6), 
153.6 (C, C-3); ESMS m/z (%): 252 (16), 213 (39), 164 (100), 138 (11), 
102 (55), 88 (4), 74(5). Analysis calculated for C9H11N3O2S: C, 47.61; H, 
4.79; N, 22.21; S, 12.71. Found: C, 47.58; H, 4.76; N, 22.24; S, 12.74.
1-(2,4-dimethyl-6-nitro-2H-benzo[b][1,4]thiazin-3(4H)-ylidene)-
2-phenylhydrazine (5e)
The title compound was prepared from 2,4-dimethyl-6-nitro-
2H-benzo[b][1,4]thiazin-3(4H)-one (4b) and phenyl hydrazine 
hydrochloride and recrystallized from ethanol. Brown crystals; yield, 
68%; m.p. 95-97°C; Rf, 0.45 (toluene-ethylacetate 3:2); UV (DMSO) 
λmax (log Ɛ) 218 (4.25) nm; IR (υ cm−1): 3393, 2899, 1701, 1593, 1525, 
1443, 1245, 828, 637; 1H-NMR (d ppm, DMSO-d6, 400 MHz): 1.20 
(d, 3H, J=7 Hz, CHCH3), 2.54 (s, 3H, N-CH3), 2.84 (q, 1H, H-2), 6.47 (2H, 
dd, J=1.6, J=8.5 Hz, H-2′,6′), 6.58-7.07 (3H, m, H-3′, H-4′, H-5′), 7.22 (1H, 
d, J=8.6 Hz, H-8), 7.31 (1H, d, J=2.5 Hz, H-5), 7.41 (1H, dd, J=2.5, 8.6 Hz, 
H-7), 10.50 (s, 1H, NH); 13C-NMR (d ppm, DMSO-d6, 100 MHz): 15.3 
(CH3, CHCH3), 30.2 (CH3, N-CH3), 35.9 (CH, C-2), 107.5 (CH, C-5), 109.6 
(CH, C-7), 116.2 (CH, C-2′, C-6′), 118.8 (C, C-4′), 123.2 (C, C-9), 127.8 
(CH, C-8), 129.6 (CH, C-3′, C-5′), 140.0 (C, C-10), 147.1 (C, C-1′), 150.4 
(C,  C-6), 153.4 (C, C-3); ESMS m/z (%): 328 (8), 289 (14), 240 (40), 
214 (7), 178 (24), 150 (100), 136 (12). Analysis calculated for 
C15H13N5O6S: C, 58.52; H, 4.91; N, 17.06; S, 9.76. Found: C, 58.57; H, 4.95; 
N, 17.02; S, 9.72.
1-(2,4-Dimethyl-6-nitro-2H-benzo[b][1,4]thiazin-3(4H)-ylidene)-
2-(2′,4′-dinitrophenyl)hydrazine (5f)
The title compound was prepared from 2,4-dimethyl-6-nitro-2H-
benzo[b][1,4]thiazin-3(4H)-one (4b) and 2,4-dinitrophenyl hydrazine 
and recrystallized from ethanol. Orange crystals; yield, 74%; m.p. 103-
105°C; Rf, 0.78 (toluene-ethylacetate 3:2); UV (DMSO) λmax (log Ɛ) 
211 (4.84) nm; IR (υ cm−1): 3294, 2924, 1687, 1585, 1422, 1044, 907; 
1H-NMR (d ppm, DMSO-d6, 400 MHz): 1.21 (d, 3H, J=7 Hz, CHCH3), 2.71 
(s, 3H, N-CH3), 2.87 (q, 1H, H-2), 7.29 (1H, d, J=8.6 Hz, H-8), 7.48 (1H, 
d, J=2.5 Hz, H-5), 7.55 (1H, dd, J=2.5, 8.6 Hz, H-7), 8.03 (1H, d, J=8.8 Hz, 
H-6′), 8.49 (1H, dd, J=2.6, 8.8 Hz, H-5′), 8.84 (1H, d, J=2.6 Hz, H-3′), 11.27 
(br, 1H, NH); 13C-NMR(d ppm, DMSO-d6, 100 MHz): 15.3 (CH3, CHCH3), 
350
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30.4 (CH3, N-CH3), 35.2 (CH, C-2), 107.5 (CH, C-5), 109.6 (CH, C-6′, C-7), 
120.7 (CH, C-3′), 126.7 (CH, C-5′), 127.8 (CH, C-8), 133.0 (C, C-9, C-2′), 
140.1 (C, C-10), 142.6 (C, C-4′), 147.4 (C, C-1′), 150.1 (C, C-6), 153.1 (C, 
C-3); ESMS m/z (%): 418 (13), 379 (11), 330 (54), 304 (7), 268 (13), 
254 (100), 136 (11). Analysis calculated for C15H13N5O6S: C, 45.93; H, 
3.37; N, 20.09; S, 7.66. Found: C, 45.91; H, 3.39; N, 20.05; S, 7.68.
General method for the synthesis of compounds 6a-f
1-(4-Methyl-6-nitro-2H-benzo[b][1,4]thiazin-3(4H)-ylidene)hydrazine 
derivative (5a-f) (0.01 mol) in glacial acetic acid (20 ml) and 30% 
hydrogen peroxide (5 ml) were added and refluxed for 15 minutes. 
Heating was stopped and another lot of hydrogen peroxide (5 ml) was 
added. The reaction mixture was again refluxed for 3-4 hrs. Excess of 
the solvent was removed by distillation under reduced pressure and 
poured into crushed ice.
1-(4-Methyl-6-nitro-2H-benzo[b][1,4]thiazin-1,1dioxide-3(4H)-
ylidene)hydrazine (6a)
The title compound was prepared by oxidation of 1-(4-methyl-6-
nitro-2H-benzo[b][1,4]thiazin-3(4H)-ylidene)hydrazine (5a) and 
recrystallized from ethanol. Yellow oil; yield, 36%; m.p. >300°C; Rf, 0.83 
(toluene-ethylacetate-ethanol 3:1:3); UV (DMSO) λmax (log Ɛ) 216 (4.55) 
nm; IR (υ cm−1): 3390, 2891, 1655, 1576, 1448, 1373, 1274, 1080, 
649; 1H-NMR (d ppm, DMSO-d6, 400 MHz): 2.73 (s, 3H, N-CH3), 3.53 (s, 
2H, H-2), 8.11 (1H, dd, J=2.5, 8.6 Hz, H-7), 8.36 (1H, d, J=8.6 Hz, H-8), 
8.59 (1H, d, J=2.5 Hz, H-5), 8.91 (s, 2H, NH2); 13C-NMR (d ppm, DMSO-d6, 
100 MHz): 30.1 (CH3, N-CH3), 50.5 (CH2, C-2), 109.6 (CH, C-5), 116.9 
(CH, C-7), 128.2 (CH, C-8), 132.9 (C, C-9), 146.7 (C, C-10), 153.7 (C, C-3, 
C-6); ESMS m/z (%): 270 (54), 199 (14), 164 (100), 138 (16), 102 (11), 
88 (8), 74(5). Analysis calculated for C9H11N3O2S: C, 40.00; H, 3.73; N, 
20.73; S, 11.86. Found: C, 40.04; H, 3.71; N, 20.71; S, 11.89.
1-(4-methyl-6-nitro-2H-benzo[b][1,4]thiazin-1,1dioxide-3(4H)-
ylidene)-2-phenylhydrazine (6b)
The title compound was prepared by oxidation of 1-(4-methyl-6-nitro-
2H-benzo[b][1,4]thiazin-3(4H)-ylidene)-2-phenylhydrazine (5b) and 
recrystallized from ethanol. Brown crystals; yield, 46%; m.p. >300°C; 
Rf, 0.37 (toluene-ethylacetate-ethanol 3:1:3); UV (DMSO) λmax (log Ɛ) 
233 (4.39) nm; IR (υ cm−1): 3362, 2884, 1657, 1578, 1419, 1374, 1231, 
1162, 1080, 649; 1H-NMR (d ppm, DMSO-d6, 400 MHz): 2.74 (s, 3H, 
N-CH3), 3.51 (s, 2H, H-2), 6.46 (2H, dd, J=1.6, J=8.5 Hz, H-2′,6′), 6.67-
7.22 (3H, m, H-3′, H-4′, H-5′), 8.21 (1H, dd, J=2.5, 8.6 Hz, H-7), 8.40 (1H, 
d, J=8.6 Hz, H-8), 8.69 (1H, d, J=2.5 Hz, H-5), 10.64 (s, 1H, NH); 13C-NMR 
(d ppm, DMSO-d6, 100 MHz): 30.9 (CH3, N-CH3), 50.9 (CH2, C-2), 109.6 
(CH, C-5), 116.3 (CH, C-2′, C-6′), 118.9 (C, C-4′), 119.7 (CH, C-7), 129.7 
(CH, C-3′, C-5′), 127.9 (CH, C-8), 133.2 (C, C-9), 147.2 (C, C-10, C-1′), 
153.5 (C, C-3, C-6); ESMS m/z (%): 346 (12), 275 (6), 226 (52), 200 (38), 
164 (23), 150 (100), 136 (12). Analysis calculated for C15H13N5O6S: C, 




The title compound was prepared by oxidation of 1-(4-methyl-6-
nitro-2H-benzo [b][1,4]thiazin-3(4H)-ylidene)-2-(2,4-dinitrophenyl)
hydrazine (5c) and recrystallized from ethanol. Orange crystals; yield, 
42%; m.p. >300°C; Rf, 0.27 (toluene-ethylacetate-ethanol 3:1:3); UV 
(DMSO) λmax (log Ɛ) 235 (4.25) nm; IR (υ cm−1): 3358, 2924, 1641, 1577, 
1404, 1325, 1248, 1144, 1051, 655; 1H-NMR (d ppm, DMSO-d6, 400 
MHz): 2.70 (s, 3H, N-CH3), 3.51 (s, 2H, H-2), 8.05 (1H, d, J=8.7 Hz, H-6′), 
8.21 (1H, dd, J=2.5, 8.6 Hz, H-7), 8.41 (1H, d, J=8.6 Hz, H-8), 8.50 (1H, 
dd, J=2.6, 8.8 Hz, H-5′), 8.71 (1H, d, J=2.5 Hz, H-5), 8.92 (1H, d, J=2.6 Hz, 
H-3′), 11.37 (br, 1H, NH); 13C-NMR(d ppm, DMSO-d6, 100 MHz): 30.5 
(CH3, N-CH3), 50.8 (CH2, C-2), 109.6 (CH, C-5), 119.6 (CH, C-6′, C-7), 
121.2 (CH, C-3′), 127.1 (CH, C-5′), 127.9 (CH, C-8), 133.3 (C, C-9, C-2′), 
142.9 (C, C-4′), 147.6 (C, C-10, C-1′), 153.7 (C, C-3, C-6); ESMS m/z (%): 
436 (11), 365 (12), 316 (52), 290 (13), 254 (100), 136 (36). Analysis 
calculated for C15H13N5O6S: C, 41.29; H, 2.77; N, 19.26; S, 7.35. Found: C, 
41.31; H, 2.73; N, 19.22; S, 7.38.
1-(2,4-Dimethyl-6-nitro-2H-benzo[b][1,4]thiazin-1,1dioxide-
3(4H)-ylidene)hydrazine (6d)
The title compound was prepared by oxidation of 1-(2,4-dimethyl-6-
nitro-2H-benzo[b][1,4]thiazin-3(4H)-ylidene)hydrazine (5d). Product 
was extracted with cyclohexane (3×50 ml) and purified by column 
chromatography on silica gel with a mixture of toluene-ethyl acetate 
(8:2) as eluent. Yellow oil; yield, 31%; Rf, 0.28 (toluene-ethylacetate-
ethanol 3:1:3); UV (DMSO) λmax (log Ɛ) 221 (4.04) nm; IR (υ cm−1): 
3362, 2828, 1692, 1523, 1339, 1245, 1186, 1062, 660; 1H-NMR (d ppm, 
DMSO-d6, 400 MHz): 1.24 (d, 3H, J=7 Hz, CHCH3), 2.63 (s, 3H, N-CH3), 
2.93 (q, 1H, H-2), 8.15 (1H, dd, J=2.5, 8.6 Hz, H-7), 8.34 (1H, d, J=8.6 Hz, 
H-8), 8.60 (1H, d, J=2.5 Hz, H-5), 8.89 (s, 2H, NH2); 13C-NMR (d ppm, 
DMSO-d6, 100 MHz): 7.3 (CH3, CHCH3), 30.7 (CH3, N-CH3), 49.6 (CH, C-2), 
109.7 (CH, C-5), 116.8 (CH, C-7), 128.1 (CH, C-8), 132.9 (C, C-9), 146.6 
(C, C-10), 153.6 (C, C-3, C-6); ESMS m/z (%): 284 (12), 213 (17), 
164 (100), 138 (23), 102 (39), 88 (7), 74(5). Analysis calculated for 
C9H11N3O2S: C, 42.25; H, 4.25; N, 19.71; S, 11.28. Found: C, 42.21; H, 4.30; 
N, 19.66; S, 11.22.
1-(2,4-Dimethyl-6-nitro-2H-benzo[b][1,4]thiazin-1,1dioxide-
3(4H)-ylidene)-2-phenylhydrazine (6e)
The title compound was prepared by oxidation of 1-(2,4-dimethyl-6-
nitro-2H-benzo[b][1,4]thiazin-3(4H)-ylidene)-2-phenylhydrazine (5e) 
and recrystallized from ethanol. Brown crystals; yield, 43%; m.p. 242-
244°C; Rf, 0.70 (toluene-ethylacetate-ethanol 3:1:3); UV (DMSO) λmax 
(log Ɛ) 244 (4.25) nm; IR (υ cm−1): 3393, 2938, 1670, 1586, 1449, 
1381.28, 1244, 1162; 1H-NMR (d ppm, DMSO-d6, 400 MHz): 1.23 (d, 
3H, J=7 Hz, CHCH3), 2.64 (s, 3H, N-CH3), 2.94 (q, 1H, H-2), 6.46 (2H, dd, 
J=1.6, J=8.5 Hz, H-2′,6′), 6.63-7.01 (3H, m, H-3′, H-4′, H-5′), 8.17 (1H, 
dd, J=2.5, 8.6 Hz, H-7), 8.39 (1H, d, J=8.6 Hz, H-8), 8.69 (1H, d, J=2.5 Hz, 
H-5), 10.61 (s, 1H, NH); 13C-NMR (d ppm, DMSO-d6, 100 MHz): 7.3 
(CH3, CHCH3), 30.8 (CH3, N-CH3), 49.9 (CH, C-2), 109.5 (CH, C-5), 116.2 
(CH, C-2′, C-6′), 118.8 (C, C-4′), 119.6 (CH, C-7), 127.8 (CH, C-8), 129.6 
(CH, C-3′, C-5′), 133.1 (C, C-9), 147.1 (C, C-10, C-1’), 153.4 (C, C-3, 
C-6); ESMS m/z (%): 360 (8), 289 (14), 240 (49), 214 (35), 178 (12), 
150 (100), 136 (15). Analysis calculated for C15H13N5O6S: C, 53.32; H, 
4.47; N, 15.55; S, 8.90. Found: C, 53.36; H, 4.42; N, 15.59; S, 8.86.
1-(2,4-Dimethyl-6-nitro-2H-benzo[b][1,4]thiazin-1,1dioxide-
3(4H)-ylidene)-2-(2′,4′-dinitrophenyl)hydrazine (6f)
The title compound was prepared by oxidation of 1-(2,4-dimethyl-6-
nitro-2H-benzo[b][1,4]thiazin-3(4H)-ylidene)-2-(2′,4′-dinitrophenyl)
hydrazine (5f) and recrystallized from ethanol. Light brown crystals; 
yield, 56%; m.p. 274-276°C; Rf, 0.78 (toluene-ethylacetate-ethanol 3:1:3); 
UV (DMSO) λmax (log Ɛ) 252 (4.20) nm; IR (υ cm−1): 3295, 2927, 1690, 
1590, 1426, 1339, 1248, 1139, 1059, 647; 1H-NMR (d ppm, DMSO-d6, 
400 MHz): 1.24 (d, 3H, CHCH3), 2.65 (s, 3H, N-CH3), 2.95 (q, 1H, H-2), 
8.04 (1H, d, J=8.8 Hz, H-6′), 8.17 (1H, dd, J=2.5, 8.6 Hz, H-7), 8.39 (1H, 
d, J=8.6 Hz, H-8), 8.49 (1H, dd, J=2.6, 8.8 Hz, H-5′), 8.69 (1H, d, J=2.5 Hz, 
H-5), 8.89 (1H, d, J=2.6 Hz, H-3′), 11.30 (s, 1H, NH); 13C-NMR(d ppm, 
DMSO-d6, 100 MHz): 7.3 (CH3, CHCH3), 30.8 (CH3, N-CH3), 49.9 (CH, C-2), 
109.5 (CH, C-5), 119.6 (CH, C-6′, C-7), 121.0 (CH, C-3′), 126.9 (CH, C-5′), 
127.8 (CH, C-8), 133.1 (C, C-9, C-2′), 142.8 (C, C-4′), 147.5 (C, C-10, C-1′), 
153.4 (C, C-3, C-6); ESMS m/z (%): 450 (13), 379 (12), 330 (52), 304 (8), 
268 (13), 254 (100), 136 (10). Analysis calculated for C15H13N5O6S: C, 
42.67; H, 3.31; N, 18.66; S, 7.12. Found: C, 42.61; H, 3.32; N, 18.62; S, 7.16.
Pharmacology
Test organism and standard drug
All standard drugs (ofloxacin and ketoconazole) were purchased 
from K K Pharmaceuticals, Udaipur, Rajasthan, whereas all the 
microorganisms (Escherichia coli, Staphylococcus aureus, Bacillus 
subtilis, Aspergillus niger, and Candida albicans) were collected from 
pathology laboratory of RNT Medical College, Udaipur, Rajasthan. All 
microbes were cultured overnight in nutrient agar medium.
In vitro antimicrobial potential assessment
In vitro antimicrobial assessment was performed by adopting the disc 
diffusion method. Representative compounds 5a-f were evaluated for 
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their antibacterial against Gram-negative bacteria, E. coli, and Gram-
positive bacteria, S. aureus, B. subtilis, and antifungal activity against 
A. niger, C. albicans at a concentration of 50 μg/ml using DMSO as a 
solvent by disc diffusion method. The antibacterial activity was 
performed with standard drug ofloxacin as positive control and DMSO 
as negative control after 24 hrs of incubation at 37°C. The antifungal 
activity was performed with ketoconazole as positive control and DMSO 
was used as negative control after 48 hrs of incubation at 25°C.
Statistical analysis
The results of the antimicrobial activity of compounds are expressed 
as mean ± SD of triplicate samples. Statistically significant differences 
between groups were measured using one-way analysis of variance 
followed by two sample t-test of all groups versus their respective 
control group and *p<0.05 was considered statistically significant, 
p>0.05 was considered as statistically non-significant, and **p<0.01 
was considered highly significant.
RESULT AND DISCUSSION
Chemistry
In IR spectra of all compounds, the bands occur in the region 
1404-1379 cm−1 and 1577-1578 cm−1 due to the symmetric and 
asymmetric stretching vibration of the nitro group. The synthesized 
4-methyl-2H-benzo[b][1,4]thiazin-3(4H)-one derivatives 4a-b exhibit a 
sharp absorption band in the region 2851-2855 due to the CH3 stretching 
and 1-(4-methyl-6-nitro-2H-benzo[b][1,4]thiazine-3-yl)hydrazines 
5a-f exhibit absorption bands in the region 3360-3100 cm−1 due to the 
stretching vibration of the secondary amino group. A weak N-N stretching 
absorption band in the region of 1106-1052 cm−1 and a strong C=N 
stretching absorption band in the 1640-1690 cm−1 region are observed.
1HNMR spectra of compounds 5a-f exhibit a multiplet in the region δ 
8.5-6.8 ppm due to aromatic protons. The broad signal observed in the 
region δ 9-11 is attributed to –NH protons. The broad peak observed at 
δ 2.6-2.8 can be assigned to –CH proton.
In IR spectra, the synthesized 1-(4-methyl-6-nitro-2H-benzo[b][1,4]
thiazine-3(4H)-ylidene)hydrazine-1,1-dioxide derivatives 6a-f exhibit 
two sharp absorption bands in the region 1195-1135 cm−1 and 1380-
1335 cm−1 due to the symmetric and asymmetric stretching vibration 
of the SO2 group.
In1 HNMR spectra, a broad peak observed in the region δ 8-11 in 
all 1-(4-methyl-6-nitro-2H-benzo[b][1,4]thiazine-3(4H)-ylidene)
hydrazine-1,1-dioxides 6a-f is due to N-H proton. Aromatic protons 
show multiplet in the region δ 6.8-8.9 ppm. The sharp peak observed 
at δ 3.2-3.4 can be assigned to –CH proton. In compounds 6a, d, a 
broad peak is observed in the region δ 8.2-8.5 due to –NH2 protons. In 
compounds 6d, e, f, a doublet peak is observed in the region 1.2-1.3 due 
to CH3 protons at C-2. 13C-NMR spectra of compounds 6a-f have been 
recorded. In mass spectra of 1-(4-methyl-6-nitro-2H-benzo[b][1,4]
thiazine-3(4H)-ylidene)hydrazine-1,1-dioxides 6a-f, the molecular ion 
peak is in accordance to their molecular weight.
Biological activity
Newly synthesized compounds 6a-f exhibited broad-spectrum 
antimicrobial activity against Gram-positive bacteria, Gram-negative 
bacterial, and fungal cultures. Antimicrobial activity was measured as 
the zone of inhibition and represented as mean ± standard deviation 
(n=3) in Table 1. Zone of inhibition is depicted in Table 1. After 
statistical analysis, p value was determined which was significant, that 
is, <0.05 (p<0.05). It has been noted that compound 6f having methyl at 
2 position and nitro groups at 2′ and 4′ position showed the most potent 
antibacterial activity, whereas compounds 6c having nitro groups at 2′ 
and 4′ position and 6e having methyl at 2 position showed moderate 
antibacterial activity as compared to reference.
In vitro evaluation of the newly synthesized compounds for the 
antimicrobial activity is the first step toward achieving the goal of 
developing a new drug for infectious disease. Earlier, the synthesis of 
many 1,4-benzothiazine derivatives and their sulfones has been reported 
to exhibit antimicrobial activity for pharmacological applications. 
Various hydrazine derivatives [15-17] have been previously reported 
possessing a broad-spectrum antimicrobial activity. In this research, 
some new class of sulfones of 1,4-benzothiazines containing different 
hydrazine derivatives in the 3-position was screened for antimicrobial 
properties. The present study through light on the antimicrobial efficacy 
Fig. 1: Synthetic pathway of 1-(4-methyl-6-nitro-2H-benzo[b][1,4]thiazine-3(4H)-ylidene)hydrazine-1,1-dioxide derivatives
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of these novel compounds. Result indicated that these synthesized 
compounds showed more activity toward bacteria as compared to the 
fungi. Results are collected in Table 1 and Graph 1 [18].
CONCLUSION
We have reported an easy method to prepare 1-(4-methyl-6-nitro-
2H-benzo[b][1,4]thiazine-3(4H)-ylidene)hydrazine-1,1-dioxide 
derivatives, using inexpensive reagents and allowing to introduce 
different hydrazine derivative in the 3-position. It has been noted 
that compound 6f showed the most potent antimicrobial activity, 
whereas compounds and 6e showed moderate antimicrobial activity as 
compared to the reference. This study may be helpful for researchers to 
further development of a new potent antimicrobial drug.
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Graph 1: Antimicrobial activity at dose 50 μg/ml
Table 1: Antimicrobial activity of compounds
Compound number Antibacterial and antifungal activity at 50 µg/ml (zone of inhibition in mm±SD)
E. coli S. aureus B. subtilis C. albicans A. niger
6a 14.33±1.53 16.33±1.16 15.67±0.58 12.67±0.58 13.33±1.53
6b 15.33±1.16 17.67±0.58 15.66±1.53 13.33±0.58 14.00±1.73
6c 16.66±1.53 18.67±0.58 17.33±1.53 15.00±0.00 15.33±0.58
6d 15.33±1.53 16.67±1.16 15.33±1.16 13.00±1.00 14.33±0.58
6e 17.33±2.52 19.66±0.58 17.66±1.53 14.33±0.58 15.67±0.58
6f 18.33±2.52 19.66±1.53 19.33±1.53 16.67±0.58 18.33±1.16
Control n. a. n. a. n. a. n. a. n. a.
Ofloxacin 21.67±0.58 22.33±0.58 20.33±1.53 - -
Ketoconazole - - - 20.33±0.58 21.67±2.08
Values are expressed as mean±SD of the three replicates. E. coli: Escherichia coli, S. aureus: Staphylococcus aureus, B. subtilis: Bacillus subtilis, C. albicans: Candida 
albicans, A. niger: Aspergillus niger, n.a: No activity, SD: Standard deviation
